Inactive Instrument

Jaguar Health Inc Share Price Nasdaq

Equities

US47008L1061

Biotechnology & Medical Research

Sales 2024 * 15.11M 1.19B Sales 2025 * 22.66M 1.78B Capitalization 71.4M 5.62B
Net income 2024 * -26M -2.05B Net income 2025 * -21M -1.65B EV / Sales 2024 * 4.73 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 3.15 x
P/E ratio 2024 *
-2.87 x
P/E ratio 2025 *
-3.69 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.62%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Founder 65 05/06/13
Director of Finance/CFO 60 30/04/19
Chief Tech/Sci/R&D Officer 60 30/04/17
Members of the board TitleAgeSince
Founder 65 05/06/13
Chairman 80 31/01/14
Director/Board Member 71 31/03/16
More insiders
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.
Calendar
More about the company